Mutual of America Capital Management LLC Has $6.24 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Mutual of America Capital Management LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,054 shares of the medical device company’s stock after acquiring an additional 1,229 shares during the period. Mutual of America Capital Management LLC’s holdings in DexCom were worth $6,242,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Team Hewins LLC lifted its position in DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after acquiring an additional 83 shares during the last quarter. Bleakley Financial Group LLC lifted its position in DexCom by 1.3% during the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after acquiring an additional 87 shares during the last quarter. Capital Insight Partners LLC lifted its position in DexCom by 2.5% during the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after acquiring an additional 90 shares during the last quarter. Gulf International Bank UK Ltd lifted its position in DexCom by 0.3% during the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after acquiring an additional 93 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in DexCom by 10.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after acquiring an additional 98 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DXCM has been the subject of several research reports. JPMorgan Chase & Co. downgraded shares of DexCom from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $145.00 to $75.00 in a research report on Friday, July 26th. UBS Group lowered their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Redburn Atlantic initiated coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 target price on shares of DexCom in a report on Monday, August 26th. Finally, Barclays lowered their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $112.25.

DexCom Stock Performance

NASDAQ DXCM opened at $70.43 on Friday. The firm’s fifty day moving average price is $78.19 and its two-hundred day moving average price is $109.63. The stock has a market cap of $28.01 billion, a PE ratio of 45.44, a PEG ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.34 earnings per share. On average, equities analysts expect that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,483 shares of company stock worth $201,708. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.